ES2296750T3 - Forma mutada de la arginina deiminasa. - Google Patents

Forma mutada de la arginina deiminasa. Download PDF

Info

Publication number
ES2296750T3
ES2296750T3 ES01932862T ES01932862T ES2296750T3 ES 2296750 T3 ES2296750 T3 ES 2296750T3 ES 01932862 T ES01932862 T ES 01932862T ES 01932862 T ES01932862 T ES 01932862T ES 2296750 T3 ES2296750 T3 ES 2296750T3
Authority
ES
Spain
Prior art keywords
arginine deiminase
baselineskip
modified
arginine
deiminase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01932862T
Other languages
English (en)
Spanish (es)
Inventor
Charles Mark Ensor
Frederick Wayne Holtsberg
Mike A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POLARIS GROUP
Polaris Group Taiwan
Original Assignee
POLARIS GROUP
Polaris Group Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POLARIS GROUP, Polaris Group Taiwan filed Critical POLARIS GROUP
Application granted granted Critical
Publication of ES2296750T3 publication Critical patent/ES2296750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Dairy Products (AREA)
ES01932862T 2000-05-04 2001-05-02 Forma mutada de la arginina deiminasa. Expired - Lifetime ES2296750T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US564559 1990-08-09
US09/564,559 US6635462B1 (en) 1997-05-12 2000-05-04 Mutated form of arginine deiminase

Publications (1)

Publication Number Publication Date
ES2296750T3 true ES2296750T3 (es) 2008-05-01

Family

ID=24254954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01932862T Expired - Lifetime ES2296750T3 (es) 2000-05-04 2001-05-02 Forma mutada de la arginina deiminasa.

Country Status (11)

Country Link
US (2) US6635462B1 (enExample)
EP (1) EP1278868B9 (enExample)
JP (1) JP4709465B2 (enExample)
AT (1) ATE382697T1 (enExample)
AU (1) AU2001259353A1 (enExample)
CY (1) CY1107351T1 (enExample)
DE (1) DE60132190T2 (enExample)
DK (1) DK1278868T3 (enExample)
ES (1) ES2296750T3 (enExample)
PT (1) PT1278868E (enExample)
WO (1) WO2001083774A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364718B1 (en) 2002-02-14 2016-07-06 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
JP4733393B2 (ja) 2002-11-18 2011-07-27 ポラリス・グループ インビボでウイルス複製を阻害する方法
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
CA2680590C (en) * 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
EP2295560A1 (en) 2009-09-14 2011-03-16 RWTH Aachen University Directed evolution of arginine deiminase for increased activity at physiological pH
US9918881B2 (en) 2011-11-22 2018-03-20 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a trough
US10118754B2 (en) * 2011-11-22 2018-11-06 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a chute
US11123230B2 (en) * 2011-11-22 2021-09-21 Kimberly-Clark Worldwide, Inc. Method of folding pant-like disposable absorbent garments in a chute
EP4582090A3 (en) 2012-04-04 2025-09-17 Polaris Group Composition comprising pegylated arginine deiminase
JP6382934B2 (ja) * 2013-03-15 2018-08-29 ポラリス グループ 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
TWI676683B (zh) * 2014-03-14 2019-11-11 開曼群島商瑞華藥業集團 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶
CN106794229B (zh) * 2014-03-18 2020-12-18 瑞华药业集团 工程化嵌合聚乙二醇化adi和使用方法
KR102730989B1 (ko) 2014-09-16 2024-11-14 티디더블유 그룹 암 치료용 adi-peg 20 항체에 대한 감소된 교차-반응성을 갖는 아르기닌 데이미나아제
CN104726478A (zh) * 2015-03-09 2015-06-24 武汉远大弘元股份有限公司 表达精氨酸脱亚胺酶基因的重组大肠杆菌及其应用
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
CN119950689A (zh) 2016-07-05 2025-05-09 北极星药业集团股份有限公司 使用精氨酸耗竭剂的组合癌症免疫疗法
WO2018085551A2 (en) 2016-11-02 2018-05-11 Polaris Group Formulations of pegylated arginine deiminase
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN112442496B (zh) * 2019-08-28 2023-05-12 江苏众红生物工程创药研究院有限公司 精氨酸脱亚胺酶突变体及其应用
CN118792288B (zh) * 2024-06-19 2025-03-04 中国医科大学附属第四医院 一种pH稳定性高的精氨酸脱亚胺酶突变体及其在肿瘤治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP2736145B2 (ja) 1990-01-11 1998-04-02 関東電化工業株式会社 パーハロゲン化エチレンの製造法
JP3209338B2 (ja) 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
CA2279986A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase

Also Published As

Publication number Publication date
DE60132190T2 (de) 2008-12-11
EP1278868A2 (en) 2003-01-29
ATE382697T1 (de) 2008-01-15
EP1278868B1 (en) 2008-01-02
PT1278868E (pt) 2008-04-11
CY1107351T1 (el) 2012-12-19
DE60132190D1 (de) 2008-02-14
US6635462B1 (en) 2003-10-21
WO2001083774A2 (en) 2001-11-08
US20040258675A1 (en) 2004-12-23
DK1278868T3 (da) 2008-05-19
AU2001259353A1 (en) 2001-11-12
JP2003533186A (ja) 2003-11-11
JP4709465B2 (ja) 2011-06-22
EP1278868B9 (en) 2008-10-29
WO2001083774A3 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
ES2296750T3 (es) Forma mutada de la arginina deiminasa.
US7323167B2 (en) Method of treatment with modified arginine deiminase
ES2255147T3 (es) Arginina deiminasa derivada de mycoplasma arthritidis y conjugados de polimeros que la contienen.
Tan et al. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy
KR102076364B1 (ko) 사람 아르기나제 및 페길화된 사람 아르기나제 및 그의 용도
USRE47233E1 (en) Albumin-binding arginine deiminase and the use thereof
CN101812438B (zh) 一种精氨酸脱亚氨酶突变体及其制备与应用
JP2009523433A (ja) 癌治療のための新規複合体
ES2856055T3 (es) Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
AU2001289132A1 (en) Modified arginine deiminase
ES2965372T3 (es) Variantes de L-asparaginasa de cobaya truncada y métodos de uso
CN101591649B (zh) 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用
WO2006015512A1 (en) A modified arginine deiminase
Tsui The development of human recombinant arginase as a novel agent in the treatment of human cancer